-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
September 2nd, 2021, San Francisco, USA and Suzhou, China-Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of tumors, metabolic diseases, autoimmunity and other major A biopharmaceutical company for innovative drugs for diseases, and Jinfang Pharmaceutical Technology (Shanghai) Co.
, Ltd.
("Jinfang Pharmaceutical"), a clinical-stage biotechnology company that develops leading therapies in the field of oncology and immunity, announced an exclusive global licensing agreement.
Cinda biological as exclusive partnership with obtaining drug candidates targeting a --GFH925 strength and western medicine is common in lung cancer and other solid tumors, cancer-causing gene KRAS G12C the drive (KRAS G12C inhibitors) in China (including mainland China, Hong Kong, Macau and Taiwan) development and commercialization rights, and have the right to choose global development and commercialization rights
.
The GFH925 independently developed by Jinfang Medicine has recently been approved by the National Medical Products Administration (NMPA) for clinical trials
.
Pre-clinical experimental data show that GFH925 has potentially best-in-class activity, which can effectively inhibit the growth of a variety of tumor cell lines carrying KRAS G12C mutations, which is conducive to accelerating clinical validation
The GFH925 independently developed by Jinfang Medicine has recently been approved by the National Medical Products Administration (NMPA) for clinical trials
According to the agreement, Cinda will be responsible for the clinical development and commercialization of GFH925 in China, and reserves the right to choose global development and commercialization rights
.
After the candidate drug is approved for marketing, Innovent will use its experienced commercialization team and extensive nationwide commercial channels to promote GFH925.
According to the agreement, Cinda Bio will pay Jinfang Pharmaceutical a down payment of US$22 million and a cumulative global development support fee of US$50 million
.
If Cinda Biologics exercises the option of global rights, it depends on reaching certain global development, registration and sales milestones.
Dr.
Liu Yongjun, President of Cinda Biotech, said: “Jingfang Medicine has rich experience in drug development and original large and small molecule new drug pipelines
.
We are very pleased to reach this strategic cooperation with Jinfang Medicine
Dr.
Dr.
Professor Wu Yilong, Life Director of Guangdong Provincial People's Hospital and Honorary Director of Guangdong Institute of Lung Cancer
About GFH925 (KRAS G12C inhibitor)
About GFH925 (KRAS G12C inhibitor) GFH925 is a high-efficiency oral new molecular entity compound independently developed by Jinfang Medicine with complete intellectual property rights.
By covalently and irreversibly modifying the cysteine residues of the KRAS G12C protein mutant, it effectively inhibits the protein-mediated GTP/GDP exchange and down-regulates The level of KRAS protein activation; preclinical cysteine selective testing also showed the highly selective inhibitory effect of GFH925 on this mutation site
.
In addition, GFH925 inhibits the KRAS protein and then inhibits downstream signal transduction pathways, effectively induces tumor cell apoptosis and cell cycle arrest, and achieves anti-tumor effects
About Cinda Bio
About Cinda Bio "Starting from the letter, reaching the line", to develop high-quality biological drugs that the common people can afford is the ideal and goal of Cinda Bio
.
Founded in 2011, Cinda Bio is committed to the development, production and sales of innovative drugs for the treatment of tumors, autoimmune, metabolic diseases and other major diseases
Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model
.
A product chain including 26 new drug varieties has been established, covering multiple disease fields such as tumors, metabolic diseases, and autoimmunity.
Cinda Bio has established an internationally advanced high-end biopharmaceutical development and industrialization talent team, including many returned experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi of South Korea.
Reach strategic cooperation
.
Cinda Bio hopes to work with everyone to improve the development level of China's biopharmaceutical industry to meet the people's access to medicines and the people's pursuit of life and health
.
For details, please visit the company's website: or the company's LinkedIn account
.
About Jinfang Medicine
About Jinfang Medicine Jinfang Medicine takes the unmet clinical needs as the starting point, with disease biological mechanisms and clinical translational medicine as the core, and in-depth study of the latest biological mechanisms in the fields of tumor signaling pathways, tumor immune microenvironment, and immune regulation.
The main attack has not yet been clinically verified.
It is committed to the development of original "global new" drugs with its innovative targets and indications, and has global independent intellectual property rights
.
Since its establishment in 2017, Jinfang Medicine has established a technology platform, research and development system and talent echelon covering large and small molecule drugs.
The product pipeline includes more than ten "global new" projects, and many drug candidates have entered China, including , The United States, Australia and other places including the global multi-center clinical research stage
.
It is expected that in the next three to five years, as more R&D projects enter the later stage of clinical research, the company will also enter the stage of industrialization
.
Forward-looking statement
The information published in this press release may contain certain forward-looking statements
.
These statements are inherently risky and uncertain
.
When using "expect," "believe," "forecast," "expect," "intend," and other similar expressions, all matters related to the company are intended to indicate that they are forward-looking statements
.
The company has no obligation to continuously update these forward-looking statements
.
These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made
.
These statements are not guarantees for future development, and will be affected by risks, uncertainties and other factors.
Some of them are beyond the control of the company and are difficult to predict
.
Therefore, due to future changes and developments in our business, competitive environment, political, economic, legal and social conditions, actual results may differ significantly from the information contained in the forward-looking statements
.
